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Abstract 1 
Chronic kidney disease is a worldwide public health concern with multi-systemic 2 
complications. We performed a trans-ethnic meta-analysis of genome-wide association 3 
studies of estimated glomerular filtration rate (eGFR, n=765,348), identifying 308 loci 4 
that explained 20% of eGFR heritability. Results were externally replicated (n=280,722) 5 
and characterized with the alternative kidney function marker blood urea nitrogen with 6 
respect to their kidney function relevance. Pathway and enrichment analyses, including 7 
genetically manipulated mice with renal phenotypes, support the kidney as the main 8 
target organ. A genetic risk score for low eGFR was significantly associated with clinical 9 
diagnosed CKD and related traits among 452,264 independent individuals. Gene 10 
expression co-localization analyses across 46 human tissues, including tubulo-11 
interstitial and glomerular kidney compartments, identified 18 kidney-specific prioritized 12 
target genes such as UMOD, KNG1, MLLT3, and GALNTL5. Fine-mapping highlighted 13 
missense driver variants in 10 genes, including several renal transporters, and a kidney-14 
specific regulatory variant in PDILT upstream of UMOD sharing associations with 15 
eGFR, UMOD expression, and urinary uromodulin levels. These results provide a 16 
comprehensive priority list of molecular targets for translational research.  17 
10 
Chronic kidney disease (CKD) is a major public health issue, with increasing incidence 1 
and prevalence worldwide.1 Its associated burden of disease encompasses metabolic 2 
disturbances, end-stage renal disease, and multisystemic complications such as 3 
cardiovascular disease.1-4 CKD is a leading cause of death5 and shows one of the 4 
highest increases in disease-attributable mortality over the last decade.2 Nevertheless, 5 
public and clinical awareness remains low.3 Moreover, clinical trials in nephrology are 6 
still underrepresented compared to other disciplines,6 resulting in scarce therapeutic 7 
options to alter disease progression and high costs for health systems.7 A major barrier 8 
to developing new therapeutics is the limited understanding of the mechanisms 9 
underlying kidney function in health and disease, and consequently in a lack of 10 
therapeutic targets. 11 
Genome-wide association studies (GWAS) and exome-chip studies of the 12 
glomerular filtration rate estimated from serum creatinine (eGFR), the main biomarker to 13 
quantify kidney function and define CKD, have shed light on the underlying mechanisms 14 
of CKD.8 Nearly one hundred genetic loci were identified in samples of European9-15, 15 
Asian16-18, and multiple19 ancestries. However, similar to other complex traits and 16 
diseases, identifying causal genes and molecular mechanisms implicated by genetic 17 
associations represents a substantial challenge and has only been successful for few 18 
kidney function-associated loci.20,21 Advanced statistical fine-mapping approaches and 19 
newly emerging gene expression data across a wide range of tissues open up new 20 
opportunities for prioritizing putative causal variants, effector genes, and target tissues, 21 
based on the results from large-scale GWAS meta-analyses.  22 
In addition, the detection of co-expressed genes as well as gene sets, cell-type 23 
specific regulatory marks and pathways that are enriched for trait-associated signals is 24 
now possible, but requires particularly large GWAS sample sizes. The largest published 25 
GWAS meta-analyses of eGFR included up to 140,000 individuals.9,10,22 However, the 26 
identified index variants only explained <4% of the eGFR variance.9,10 A substantial 27 
expansion of study sample size, inclusion of more diverse populations, and more 28 
comprehensive coverage of genetic variants promise to identify novel loci, increase the 29 
explained variance of eGFR, and detect disease-relevant pathways and co-regulation 30 
with other complex traits. 31 
11 
We therefore carried out a trans-ethnic meta-analysis of GWAS of eGFR from 1 
765,348 individuals in order to maximize statistical power to identify novel eGFR-2 
associated loci, which were globally representative loci. Generalizability of results was 3 
evaluated through replication in an independent study of 280,722 individuals, for a 4 
combined sample size of >1 million participants, and with genetic risk score analyses of 5 
clinical diagnoses of kidney disease in an independent sample of 452,264 individuals. 6 
Associated loci were characterized through a complementary kidney function marker, 7 
blood urea nitrogen (BUN), which was used to prioritize loci with respect to their kidney 8 
function relevance. To identify most likely causal variants, genes, and mechanisms, we 9 
performed enrichment and network analyses, statistical fine-mapping, and integration of 10 
gene expression in kidney and 44 other tissues. The resulting list of functionally relevant 11 
variants, genes, tissues and pathways provides a rich resource of potential therapeutic 12 
targets to improve CKD treatment and prevention.  13 
 14 
Results  15 
Overview 16 
Within the CKD Genetics (CKDGen) Consortium, we established a collaborative, 17 
standardized and automated analysis workflow to integrate results from 121 eGFR 18 
GWAS of five ancestry groups (Supplementary Table 1). Our effort served two 19 
objectives (Supplementary Figure 1): first, we aimed at identifying novel, globally 20 
representative loci for kidney function through meta-analysis of trans-ethnic samples; 21 
second, we aimed to understand each locus in depth through complementary 22 
computational approaches, including various enrichment analyses, statistical fine-23 
mapping and co-localization with gene expression and protein levels in urine, among 24 
European ancestry (EA) individuals, for whom large reference panels on linkage 25 
disequilibrium (LD) structure are available.  26 
 27 
Identification of 308 loci associated with eGFR through trans-ethnic meta-analysis  28 
12 
In total, the 121 GWAS included data from 765,348 individuals (567,460 EA, 165,726 of 1 
East Asian ancestry, 13,842 African Americans, 13,359 of South Asian ancestry, and 2 
4,961 Hispanics, Supplementary Table 1). The median of the study-specific mean 3 
eGFR was 89 ml/min/1.73m² (1st (Q1) and 3rd (Q3) quartiles: 81, 94), the median age 4 
was 54 years, and 50% were female. GWAS of eGFR were based on genotypes 5 
imputed using reference panels from the Haplotype Reference Consortium (HRC)23 or 6 
the 1000 Genomes Project24 (Methods, Supplementary Table 2). Following study-7 
specific variant filtering and quality control procedures, fixed-effects inverse-variance 8 
weighted meta-analysis was conducted (Methods). There was no apparent evidence of 9 
stratification (LD Score regression intercept =1.04; λGC=1.05). After variant filtering, 10 
8,221,591 single nucleotide polymorphisms (SNPs) were used for analysis (Methods). 11 
We identified 308 loci containing at least one SNP associated with eGFR at 12 
genome-wide significance (P<5×10-8). Loci were defined as ±500 kb around the SNP 13 
with the lowest p-value (index SNP); the extended MHC region was considered as a 14 
single locus (Methods). Of these loci, 200 were novel and 108 were considered known 15 
because they contained an index SNP reported by previous GWAS of eGFR (Figure 1). 16 
Association statistics for all 308 index SNPs are shown in Supplementary Table 3 and 17 
the corresponding regional association plots in Supplementary Figure 2. The minor 18 
alleles across index SNPs showed both decreasing and increasing effects on eGFR 19 
(Figure 1, inset). Taken together, the 308 index SNPs explained 7.1% of the eGFR 20 
variance (Methods), nearly doubling the estimate from a recent eGFR GWAS meta-21 
analysis.9 These SNPs explained 19.6% of the genetic heritability of eGFR (h2=39%, 22 
95% credible interval: 32%, 47%) estimated in a large participating general-population-23 
based pedigree-study (Supplementary Figure 3A; Methods).  24 
Most of the 308 index SNPs showed homogeneous effects across studies 25 
(median I2 =5%, Q1, Q3: 0, 13%; Supplementary Table 3; Fig 2A). Only one index 26 
SNP had I2 >50% (UMOD-PDILT locus, I2=60%) as described previously;10,13 27 
heterogeneity is suspected to be age-related.25 We then investigated the heterogeneity 28 
of genetic effects that was correlated with ancestry using meta-regression26 (Methods) 29 
and identified three index SNPs with significant ancestry-related heterogeneity at the 30 
LINC01362, GATM, and PSD4 loci (ancestry heterogeneity p-value (p-anc-het) 31 
13 
<0.05/308; Figure 2A, Supplementary Table 3). The index SNP at UMOD-PDILT did 1 
not show evidence for ancestry-related heterogeneity (p-anc-het=0.59). These results 2 
suggest similar effects across ancestries for the vast majority of the identified SNPs. 3 
Ancestry-specific results for all 308 index SNPs are reported in Supplementary Table 4 
4. 5 
 6 
Generalizability of eGFR-associated SNPs and meta-analysis of >1 million individuals 7 
Next, we assessed whether the trans-ethnic findings were generalizable to other, 8 
independent trans-ethnic samples, using data from a GWAS meta-analysis of eGFR 9 
performed among 280,722 participants of the Million Veteran Program (MVP) from US 10 
Veterans’ Administration facilities.27 The MVP sample consisted of 20.4% African 11 
American and 79.6% EA participants (mean age 64 years, 7.4% females; Methods). 12 
Despite differences in source population, ancestry and sex composition, and analytical 13 
strategies between CKDGen and MVP, associations at 262 of the 305 SNPs replicated 14 
(1-sided replication P<0.05 and P<5×10-8 in the meta-analysis of CKDGen and MVP; 15 
Figure 1; Supplementary Table 3; Methods). Of note, 10 SNPs that were not 16 
replicated were previously reported in other GWAS of eGFR, which generally included a 17 
replication stage. They may therefore represent true associations that did not replicate 18 
in the MVP because of differences between the two studies. Generalizability of the 305 19 
SNPs was further supported by the almost perfect direction consistency of the eGFR 20 
effect estimates in CKDGen and MVP (302/305 SNPs, 99%; Figure 2B), and the very 21 
strong correlation of the genetic effects (Pearson’s correlation coefficient ρ=0.92, 95% 22 
confidence interval (CI): 0.90, 0.94; Figure 2B). Seventy-four SNPs were genome-wide 23 
significant in MVP alone (Supplementary Table 3). The meta-analysis of CKDGen and 24 
MVP comprising a total of 1,038,119 individuals showed genome-wide significance for 25 
94% of the 305 SNPs (Supplementary Table 3), with the lowest p-value being 26 
observed for SNP rs77924615 at UMOD-PDILT (P=3×10-259). Together, these results 27 
support the robustness of our findings even in a setting of a smaller independent study 28 
with differences in ancestral and sex composition, trait transformation, and modeling 29 
(Methods).  30 
14 
 1 
Clinical and epidemiological landscape: association of eGFR index SNPs with blood 2 
urea nitrogen (BUN) and CKD  3 
To evaluate whether the eGFR index SNPs pertained to kidney function rather than 4 
creatinine metabolism, we assessed their relation to BUN, an alternative marker of 5 
kidney function that is inversely correlated with eGFR. We performed fixed-effect meta-6 
analysis of GWAS of BUN combining 416,178 samples from 65 studies 7 
(Supplementary Table 1) across 5 ancestries, using the same workflow as for eGFR.  8 
Overall, the GWAS meta-analysis of BUN showed no evidence of stratification 9 
(λGC=1.03; LD Score regression intercept =0.98) and yielded 111 genome-wide 10 
significant loci (15 known, 96 novel, Supplementary Figure 4, Supplementary Table 11 
6). The 262 replicated eGFR index SNPs showed an inverse correlation with BUN (ρ=-12 
0.65, 95%CI: -0.72, -0.58). Evidence of their relevance to kidney function was classified 13 
as strong for 148 eGFR index SNPs that showed inverse, significant (one-sided P<0.05) 14 
associations with BUN; inconclusive for 102 eGFR index SNPs that were not 15 
significantly associated with BUN (P≥0.05); and unlikely for 15 eGFR index SNPs 16 
showing concordant, significant (one-sided P<0.05) association with BUN (Figure 2C, 17 
Supplementary Table 5). This comparative analysis of complementary markers of 18 
kidney function supports that signals at most of the eGFR-associated index SNPs likely 19 
reflect relevance for kidney function rather than marker metabolism. 20 
Next, we investigated the odds ratios (OR) for CKD, defined as eGFR <60 21 
ml/min/1.73m2, for all eGFR index SNPs. We performed a GWAS meta-analysis of CKD 22 
in 625,219 individuals (64,164 CKD cases) from the same studies used for eGFR 23 
analysis (Methods). Of the 262 replicated eGFR index SNPs, 222 were significantly 24 
associated with CKD (1-sided P<0.05, Figure 1, inset), including 128 with strong 25 
evidence of kidney-function relevance as classified by their association with BUN 26 
(Supplementary Table 5). Twenty-three loci were associated with CKD at genome-27 
wide significance level. Of them, two haven’t been found in previous GWAS of eGFR or 28 
CKD,  and 17 showed strong support for kidney function relevance, at SDCCAG8, 29 
PSD4, HOXD8, FGF5, DAB2, SLC34A1, UNCX, PRKAG2, LARP4B, DCDC1, WDR72, 30 
15 
UMOD-PDILT, MYO19, AQP4, NFATC1, and NRIP1 (Supplementary Table 5). The 1 
largest effects on CKD were observed for rs77924615 at UMOD-PDILT (OR=0.81, 2 
95%CI: 0.80; 0.83), rs187355703 at HOXD8 (OR=0.82, 95%CI: 0.77; 0.87), and 3 
rs10254101 at PRKAG2 (OR=1.11, 95%CI: 1.09; 1.11). 4 
Lastly, we carried out a genetic risk score (GRS) analysis in a large, independent 5 
dataset of 452,264 participants of the UK Biobank to assess the combined effect of 6 
identified eGFR index SNPs on clinically diagnosed CKD and CKD related outcomes 7 
including hypertension, defined by ICD-10 codes (Methods). Each standard deviation 8 
higher GRS, constructed based on effect-size weighted alleles associated with lower 9 
eGFR across the index SNPs, was significantly associated with higher odds of chronic 10 
renal failure (OR 1.08, 95%CI: 1.07, 1.09; P=8.7x10-59). Moreover, the GRS also 11 
showed positive and significant associations with glomerular diseases, acute renal 12 
failure, and hypertensive diseases, but not with asthma or schizophrenia that were 13 
included as negative controls (Figure 2D, Supplementary Figure 5). There was a 14 
significant protective association with urolithiasis, which may reflect a reduced ability to 15 
concentrate urine at lower eGFR.  16 
 17 
Genetic correlations of eGFR and BUN with other complex traits and diseases 18 
Lower eGFR is associated with numerous cardio-metabolic risk markers and 19 
diseases.4 We therefore assessed the evidence for a shared genetic basis or co-20 
regulation by evaluating genetic correlations (rg) of the trans-ethnic GWAS meta-21 
analysis results with those from 749 other complex traits and diseases available through 22 
LD Hub using LD score regression (Methods).28 For eGFR, we observed 37 significant 23 
genetic correlations (P<6.7×10-5 = 0.05/749, Supplementary Figure 6; Supplementary 24 
Table 8). Other than with serum creatinine, the largest negative genetic correlations 25 
were observed for serum citrate (rg=-0.27) and urate (rg=-0.23), followed by 26 
anthropometric traits including lean mass and physical fitness (e.g., rg=-0.20 with left 27 
hand grip strength). While the inverse genetic correlation with muscle mass-related 28 
traits likely reflects higher creatinine generation leading to lower creatinine-based 29 
eGFR, the genetic correlations with blood concentrations of the metabolites citrate and 30 
16 
urate likely reflect reduced filtration function, as does the positive genetic correlation 1 
with GFR estimated from cystatin C (rg=0.53). No significant genetic correlations were 2 
observed with cardiovascular traits and diseases. Sensitivity analyses using only EA-3 
specific summary statistics delivered very similar results (data not shown). For BUN, a 4 
very similar pattern of genetic correlations with the 748 other complex traits and 5 
diseases was observed as for eGFR (Supplementary Table 8). Importantly, the 6 
strongest genome-wide genetic correlation across all traits was observed with CKD 7 
(rg=0.47). 8 
In summary, significant genetic correlations with eGFR reflect the two biological 9 
components that govern serum creatinine concentrations: its excretion via the kidney 10 
and its generation in muscle. The high proportion of traits and diseases that show 11 
significant genetic correlations with both eGFR and BUN support the use of BUN as a 12 
comparative biomarker to prioritize loci most likely to reflect effects on kidney function 13 
rather than marker metabolism. 14 
 15 
Functional enrichment and pathway analyses 16 
To identify previously unknown molecular mechanisms and tissues of importance for 17 
kidney function, we assessed the enrichment of the eGFR and BUN genetic 18 
associations using tissue-specific gene expression, regulatory annotations, and gene 19 
sets and pathways (Methods).   20 
First, we used all eGFR-associated SNPs with P<5×10-8 to explore enriched 21 
pathways, tissues and cell types based on gene expression data using DEPICT.29 We 22 
identified 16 significantly enriched physiological systems, cell types and tissues 23 
highlighting several aspects of kidney function, physiology and disease. The strongest 24 
enrichment was observed for urogenital and renal physiological systems and tissues 25 
(kidney, kidney cortex, and urinary tract; false discovery rate (FDR) <0.05; 26 
Supplementary Figure 7A and B), which is proof-of-concept of the kidney as the 27 
primary target organ. We additionally found significant enrichment for mucous 28 
membrane, respiratory mucosa, nasal mucosa, and nose (enrichment p-values from 29 
3.1×10-4 to 1.2×10-3), possibly reflecting epithelial cell processes including transport 30 
17 
mechanisms that are shared with the kidney. Pathway and gene set enrichment 1 
analysis identified three highly correlated and strongly associated meta gene sets 2 
(P<1×10-6, FDR<0.05), including some relevant to kidney such as polyuria, dilated renal 3 
tubules, and expanded mesangial matrix, as well as signaling and transcription, and 4 
energy metabolism (Supplementary Figure 7C). Tissue and cell-type enrichment 5 
analysis of BUN-associated SNPs with P<5×10-8 highlighted a very similar pattern to the 6 
one observed for eGFR: the strongest enrichment was observed for urogenital and 7 
renal physiological systems and tissues (Supplementary Figure 8), and significant 8 
enrichment was also observed for mucous membrane, respiratory mucosa, nasal 9 
mucosa, nose, epithelial cells and the epithelium. In contrast, we did not observe 10 
enrichment for muscle tissues as was observed for eGFR, further supporting the use of 11 
BUN to prioritize loci most likely to be related to kidney function rather than creatinine 12 
metabolism. 13 
Second, we used the genome-wide eGFR and BUN summary statistics to identify 14 
cell-type groups with evidence for enriched heritability based on data from diverse, cell-15 
type specific functional genomic elements using stratified LD Score regression.30 Across 16 
10 evaluated cell type groups, the strongest and most significant enrichment for eGFR 17 
was observed for kidney (13.2-fold), followed by liver (7.3-fold) and adrenal/pancreas 18 
(5.7-fold enrichment; Supplementary Table 9). Kidney cell types were also the most 19 
enriched cell type group for BUN (significant 11.5-fold enrichment; Supplementary 20 
Table 9). These analyses based on regulatory marks confirm the importance of the 21 
kidney as a target organ. 22 
Lastly, we took a complementary approach to assess enrichment of eGFR-23 
associated variants in genes resulting in kidney phenotypes in genetically manipulated 24 
mice.31 We selected all genes from the Mouse Genome Informatics database that - 25 
when genetically manipulated - cause abnormal GFR (n=24), abnormal kidney 26 
physiology (n=453), or abnormal kidney morphology (n=764). Human orthologs for 27 
these genes were interrogated in the eGFR summary statistics for the presence of 28 
significant associations (Methods). We identified associations in 10 genes causing 29 
abnormal GFR in mice (enrichment p-value=8.9×10-4), 55 causing abnormal kidney 30 
physiology (enrichment p-value=1.1×10-4) and 96 causing abnormal kidney morphology 31 
18 
(enrichment p-value=1.8×10-5; Figure 3, Methods). Of these, 25 genes were novel, i.e. 1 
these genes had not previously been shown to contain SNPs associated with eGFR at 2 
genome-wide significance or map near known loci (Supplementary Table 10). These 3 
genes therefore represent additional novel eGFR-associated candidates in humans. 4 
The existing mouse models may pave the way for experimental confirmation of these 5 
findings. 6 
 7 
Statistical fine-mapping and second signal analysis in EA individuals 8 
To effectively fine-map loci using summary statistics, the LD reference panel needs to 9 
be ancestry-matched to the GWAS population and the sample size of the LD reference 10 
panel should scale with that of the GWAS.32 Accordingly, conditional and fine-mapping 11 
analyses were only carried out among EA participants, for whom data to construct a 12 
large enough LD reference panel is publicly available; 15,000 EA individuals from the 13 
UK Biobank were randomly selected for this purpose (Methods).  14 
The meta-analysis of the 85 EA GWAS studies identified 256 genome-wide 15 
significant loci (Supplementary Table 11). Combining neighboring loci whose index 16 
SNPs were correlated (r2≥0.2) resulted in 212 non-overlapping regions. Among these 17 
regions, 277 independent genome-wide significant SNPs were identified (Methods, 18 
Supplementary Table 12), that explained 6.8% of the eGFR variance and 23.2% of 19 
eGFR genetic heritability in EA (Supplementary Figure 3B). For each of the 277 20 
independent variants, we computed a 99% credible set, that is, a set which contains the 21 
SNP driving the association with 99% probability.33 The median number of SNPs per 22 
credible set was 30 (Q1, Q3: 7, 74). Twenty credible sets contained only a single SNP 23 
(at EDEM3, CACNA1S, HOXD11, CPS1, DAB2, SLC34A1, LINC01512, LARP4B, 24 
DCDC1, SLC25A45, SLC6A13, GATM, CGNL1, CYP1A1, NRG4, RPL3L, UMOD-25 
PDILT, SLC47A1), and two independent sets with a single SNP each at BCL2L14 26 
(Supplementary Table 12; Figure 4), and 58 sets contained ≤5 SNPs (small credible 27 
set). 28 
To ensure that loci we prioritize for further functional studies represent robust 29 
findings with likely relevance for kidney function, selected credible sets were restricted 30 
19 
to those based on SNPs that replicated in the MVP and which showed tier 1 or 2 1 
relevance for kidney function. Associations at the 256 EA-specific index SNPs were 2 
therefore tested for replication in the EA subsample of the MVP using the same criteria 3 
as in the trans-ethnic analysis, and confirmed association at 228 loci (Methods, 4 
Supplementary Table 11). GWAS meta-analysis of BUN was performed in 243,029 EA 5 
individuals, and BUN association results at 15 of 228 replicated eGFR index SNPs 6 
indicated that these were unlikely to be related to kidney function (Supplementary 7 
Table 11). This left 253 credible sets that contain genes and SNPs that can be 8 
prioritized for further study (Supplementary Table 12). 9 
To systematically examine the characteristics of the SNPs in the credible sets, 10 
SNPs were annotated with respect to their functional consequence and regulatory 11 
potential. Missense SNPs with a posterior probability of >50% of driving the association 12 
and/or mapping into a small credible set are of particular interest because they directly 13 
implicate the affected gene. Such missense SNPs were identified in 11 genes 14 
(SLC47A1, RPL3L, SLC25A45, CACNA1S, EDEM3, CPS1, KLHDC7A, PPM1J, 15 
CERS2, C9, and SLC22A2; Supplementary Table 13). Most of these variants had 16 
CADD scores >15 (Figure 4A, Table 1), a cutoff used to indicate deleteriousness.34 As 17 
summarized in Table 1, several of the identified genes are plausible biological 18 
candidates. For example, the missense p.Ala465Val SNP in SLC47A1 (posterior 19 
probability >99%) encodes an amino acid change of the encoded multidrug and toxin 20 
extrusion protein (MATE1). This transport protein is responsible for the secretion of 21 
cationic drugs, toxins and internal metabolites including creatinine across brush border 22 
membranes including kidney proximal tubules. The fact that MATE1 knockout mice 23 
have higher blood levels of both creatinine and BUN35 argues against a sole effect on 24 
creatinine transport. Altered ability to excrete toxic compounds via kidney tubular cells 25 
may also be the molecular mechanisms underlying the association signal at another 26 
fine-mapped missense SNP, p.Ser270Ala in SLC22A2 (Table 1). 27 
 Emerging experimental evidence provides molecular mechanisms by which 28 
regulatory variants identified from GWAS exert their effects.36 To evaluate whether 29 
small credible set SNPs may have regulatory potential in the kidney, we annotated them 30 
to regions of open chromatin identified from primary cultures of human tubular and 31 
20 
glomerular cells (GEO accession number GSE115961), as well as from publicly 1 
available kidney cells types (ENCODE and Roadmaps Projects; Methods). We identified 2 
63 SNPs in 39 credible sets that mapped into one of these annotations and may thus 3 
represent causal regulatory variants (Supplementary Table 13). A finding of particular 4 
interest was intronic rs77924615 in PDILT. This SNP had a posterior probability of 5 
>99% of driving the association signal at the well-established UMOD locus. It mapped 6 
into open chromatin in all evaluated resources (native kidney cells, ENCODE and 7 
Roadmap kidney cell types), implicating rs77924615 as a candidate causal regulatory 8 
variant (Figure 4B) associated with differential expression of uromodulin, the product of 9 
the neighboring UMOD gene, but not with the PDILT transcript in any tissue.  10 
 11 
Gene prioritization via gene expression co-localization analysis  12 
A complementary approach to highlight target genes in associated loci is to 13 
systematically evaluate co-localization of the genetic associations with phenotype and 14 
gene expression (expression quantitative trait locus, eQTL) in cis. We performed co-15 
localization analyses for each eGFR-associated locus with gene expression across 46 16 
tissues including kidney glomerular and tubulo-interstitial compartments (Methods). A 17 
high posterior probability of >80% for co-localization of eGFR and eQTL signals in at 18 
least one kidney tissue was observed for 20 transcripts (Figure 5), pointing towards a 19 
shared underlying SNP and implicating the gene encoding for the co-localized transcript 20 
as the locus’ effector gene(s).  21 
Novel insights emerged on several levels: first, UMOD is a well-established 22 
causal gene for CKD in the associated GWAS locus and can therefore serve as a 23 
validation of the workflow. In the tubulo-interstitial kidney compartment, we observed 24 
evidence for a shared underlying variant associated with higher UMOD gene expression 25 
and lower eGFR (Figure 5). This is consistent with previous GWAS of urinary 26 
uromodulin concentrations, in which alleles associated with lower eGFR at UMOD15 27 
were associated with higher urinary uromodulin concentrations.37 The lead SNP at this 28 
locus was rs77924615, highlighted above as the candidate causal regulatory variant 29 
mapping into the intron of PDILT, the gene upstream of UMOD. The association with 30 
21 
differential UMOD but not PDILT gene expression supports UMOD as the causal gene 1 
at this locus and rs77924615 as a regulatory SNP. It also illustrates the value of 2 
studying gene expression in diverse tissues, as this kidney-specific co-localization 3 
would have been missed had target tissue not been studied.  4 
Second, novel, biologically plausible candidates emerged. For example, our 5 
results suggest that KNG1 and FGF5 are the effector genes in the respective eGFR-6 
associated loci (Figure 5, Supplementary Table 14). KNG1 encodes for high-7 
molecular weight kininogen, which among other functions releases bradykinin. 8 
Bradykinin in turn influences blood pressure, natriuresis and diuresis, and can be linked 9 
to kidney function via the connection to the renin-angiotensin-aldosterone system.38 10 
Independent variants (r2<0.1) at the KNG1 locus have been identified in GWAS of 11 
plasma renin and aldosterone concentrations,39 and a perfect proxy of the KNG1 index 12 
SNP was reported in GWAS of adiponectin concentrations.40 FGF5 encodes for 13 
Fibroblast Growth Factor 5, and the index SNPs for eGFR or highly correlated SNPs 14 
(r2>0.9) have been identified in multiple GWAS of blood pressure, atrial fibrillation, 15 
coronary artery disease, hematocrit and multiple kidney-function related traits 16 
(Supplementary Table 14). The eGFR index SNP, rs1458038, has a posterior 17 
probability of >50% of driving the association signal with eGFR and has a CADD score 18 
of 14.8 (Supplementary Table 14, supporting its regulatory potential on the expression 19 
levels of FGF5 transcript levels, which co-localized with the eGFR signal only in tubule-20 
interstitial kidney portions (Figure 5). Index SNPs at both KNG1 and FGF5 are likely to 21 
be related to kidney function as they also show associations with BUN and CKD. 22 
Examination of gene expression across multiple tissues types revealed some of 23 
the kidney-colocalized genes showed directionally consistent transcript levels across all 24 
tissues (e.g. METTL10), while other kidney-colocalized genes were bidirectional, with 25 
higher transcript levels in some tissues, but lower in others (e.g. SH3YL1) (Figure 5). 26 
These observations were also reflected broadly across all genes with evidence of 27 
colocalization in any tissue (Supplementary Figure 8), and highlight tissue-shared and 28 
tissue-specific signals.41,42 29 
22 
Trans-eQTL annotation of the index SNPs was only performed using whole blood 1 
and peripheral blood mononuclear cells, for which eQTL datasets with large sample size 2 
were available (Methods). Based on the analysis of 5 non-overlapping EA genome-wide 3 
eQTL studies (sample size range 1469 - 6645, Supplementary Table 15), we identified 4 
a reproducible link of rs17696736 (12q24.12) with both the calcium-binding protein gene 5 
S100A10 (1q21.3) and STAT1 (2q32.2). S100A10 encodes a subunit of annexin A2, 6 
which co-localizes with PLA2R at the cell surface and in extracellular vesicles from 7 
podocytes.43 Inhibition of STAT1 has been reported to protect from glomerular 8 
mesangial cell senescence44 and to ameliorate renal oxidative stress45 (Supplementary 9 
Table 16). 10 
 11 
Co-localization with protein levels supports UMOD as a target gene  12 
The UMOD locus is of particular clinical interest for CKD research:20 rare UMOD 13 
mutations cause autosomal-dominant tubulo-interstitial kidney disease46 and common 14 
variants at UMOD give rise to the strongest signal in GWAS of eGFR and CKD.15 We 15 
therefore investigated this locus in further detail: conditional analyses based on the EA-16 
specific summary statistics indicated the presence of two independent variants at this 17 
locus (Figure 6A), with rs77924615 mapping into upstream PDILT, and rs34882080 18 
mapping into an intron of UMOD. Association results for the urinary uromodulin-to-19 
creatinine ratio (UUCR) in one of the participating cohorts gave a similar appearance 20 
(Figure 6B) with rs34262842 (r2 with rs34882080 0.93) as the lead variant. Co-21 
localization of the associations with eGFR and with UUCR was evaluated separately for 22 
the two independent signals, the one with lead variants in UMOD (Figure 6C) and the 23 
one represented by rs77924615 in PDILT (Figure 6D). In both regions, there was a high 24 
probability of a shared underlying variant (posterior probabilities of 0.97 and 0.96, 25 
respectively), further supporting rs77924615 as a causal regulatory variant and UMOD 26 
as its effector gene.  27 
 28 
  29 
23 
Discussion  1 
This trans-ethnic study represents a 5-fold increase in sample size compared to 2 
previous GWAS meta-analyses of eGFR and identified 308 eGFR-associated loci, of 3 
which 200 are reported here for the first time. The index SNPs at these loci explain 4 
almost twice as much eGFR variance as previously reported.9,10,22 By using 5 
complementary kidney function traits, we highlight loci that most likely reflect the 6 
kidney’s filtration function and provide a comprehensive annotation resource. Our 7 
enrichment analyses confirm the kidney as the main target tissue of the detected SNPs, 8 
and co-localization with gene expression in kidney prioritize 18 potential target genes for 9 
follow-up. Conditional analyses followed by statistical fine-mapping and annotation 10 
implicated a single potentially causal SNP in 20 independent loci, and identified 10 11 
missense SNPs directly implicating RPL3L, CACNA1S,  CERS2 and C9 as effector 12 
genes. The increase in resolution from locus to single potentially causal variant with its 13 
effector gene and target tissue, as illustrated by in depth analysis of the UMOD locus, 14 
represents a critical advance in the field and is a prerequisite for translational research. 15 
 Most previous meta-analyses of GWAS of eGFR were limited to a single 16 
ancestry group8 and did not prioritize causal variants or effector genes in associated 17 
loci. While being underpowered to uncover novel loci, one previous trans-ethnic study 18 
employed statistical fine-mapping and resolved one signal to a single variant,19 19 
rs77924615 at UMOD-PDILT, also identified in our study. At this locus, we further 20 
characterized the relationship between the causal variant at PDILT, UMOD expression 21 
in the target tissue, and UMOD protein levels. This represents a significant 22 
advancement over the course of 10 years of eGFR GWAS15 and highlights the utility of 23 
the generated resources. 24 
Our complementary multi-tissue approaches including enrichment analyses 25 
based on gene expression, regulatory annotations, and gene sets and pathways 26 
highlight the kidney as the most important target organ. However, relatively few kidney-27 
specific experimental datasets are publicly available as compared to other organs and 28 
tissues. For example, the kidney is not well represented in the GTEx Project and not 29 
included in its tissue-specific eQTL datasets,41 which emphasizes the value of open 30 
24 
access resources and in depth characterization of uncommon tissues and cell types. 1 
We were able to specifically investigate the kidney by using a recently published eQTL 2 
dataset from glomerular and tubulo-interstitial portions of micro-dissected human kidney 3 
biopsies,47 kidney-specific regulatory information from the ENCODE and Roadmap 4 
resources, and by obtaining regulatory information from primary cultures of human 5 
glomerular and tubulo-interstitial cells. 6 
Functional follow-up studies of potentially causal variants will benefit from 7 
prioritized loci that show clear evidence supporting one or a few variants driving the 8 
association signal. Our statistical fine-mapping workflow allowed us to prioritize such 9 
variants at single-variant resolution for 20 loci, and down to a set of ≤5 SNPs for 38 10 
additional loci. For example, the OCT2 protein encoded by the prioritized SLC22A2 11 
gene is known to transport several cationic drugs such as metoprolol, cisplatin, 12 
metformin and cimetidine across the basolateral membrane of renal tubular cells.48 The 13 
p.Ser270Ala SNP prioritized by our workflow is a known pharmacogenomic variant that 14 
alters the transport of these drugs and their side-effects, such as cisplatin-induced 15 
nephrotoxicity.49 Some of these drugs are commonly prescribed to CKD patients and 16 
may be of relevance given their already reduced eGFR. Along the same lines, the 17 
prioritized p.Ala465Val SNP in SLC47A1 that encodes the transporter MATE1 protein 18 
may affect the ability to secrete drugs and other toxins from proximal tubular cells into 19 
the urine50 and hence alter CKD risk.  20 
 Strengths of this project include the large trans-ethnic sample size with dense 21 
genotype imputation, a standardized and automated phenotype generation and quality 22 
control workflow, the use of an alternative biomarker of kidney function to prioritize 23 
associated loci with respect to their kidney function relevance, associations of a genetic 24 
risk score for low eGFR with CKD and related diagnoses in a large independent 25 
population, and advanced and comprehensive downstream bioinformatics analyses to 26 
prioritize causal genes and SNPs across tissues. Some limitations warrant mention. 27 
Non-European populations were still underrepresented in our study, emphasizing the 28 
need study more diverse populations51 and highlighting the potential of future trans-29 
ethnic efforts with trans-ethnic fine-mapping analyses once larger reference panels to 30 
estimate population-specific LD become available. Several SNPs had small effective 31 
25 
sample sizes in some of the subpopulations, which might have affected the ability to 1 
assess between-ancestry heterogeneity and potentially resulted in an underestimation 2 
of true heterogeneity. We used GFR estimated from serum creatinine, as done in 3 
clinical practice and observational studies, because direct measurement of kidney 4 
function is invasive, time-consuming, and burdensome. We carefully calibrated 5 
creatinine across studies, used state-of-the-art estimating equations, and distributed a 6 
centrally generated and automated script for GFR phenotype computation that all 7 
participating studies used. We also evaluated genetic associations with a 8 
complementary marker of kidney function, BUN. In addition, the generated genome-9 
wide BUN summary statistics represent a useful resource for other studies in the field 10 
that evaluate only one kidney function biomarker, typically eGFR, or for researchers 11 
interested in organ-specific functions. To favor the identification of signals and variants 12 
that are broadly representative and generalizable, our analysis focused on SNPs that 13 
were present in the majority of the participating studies. This choice might have limited 14 
our ability to uncover novel or to fine-map low-frequency or population-specific variants, 15 
which represents a complementary avenue of research. Moreover, even with well-16 
powered statistical fine-mapping approaches, prioritized variants estimated as 17 
underlying the association signals need to be confirmed as causal variants in 18 
experimental studies. Although co-localization with gene expression can help prioritize 19 
effector genes, these associations are based on measures from a single time point and 20 
hence cannot answer whether changes in gene expression precede changes in kidney 21 
function or occur as a consequence.  22 
In summary, we identified and characterized 308 loci associated with eGFR and 23 
prioritized potential effector genes, driver variants and target tissues. These findings will 24 
help direct functional studies and advance the understanding of kidney function biology, 25 
a prerequisite to develop novel therapies to reduce the burden of CKD.  26 
26 
Online Methods 1 
Overview 2 
We set up a collaborative meta-analysis based on a distributive data model and quality 3 
control (QC) procedures. To maximize the level of standardization of generated 4 
phenotypes across studies, an analysis plan and a command line script 5 
(https://github.com/genepi-freiburg/ckdgen-pheno) were created centrally and provided 6 
to all participating studies, which were mostly population-based (Supplementary Table 7 
1). Instructions for data processing, analysis and troubleshooting were distributed to all 8 
studies via a Wiki system 9 
(https://ckdgen.eurac.edu/mediawiki/index.php/CKDGen_Round_4_EPACTS_analysis_10 
plan). Automatically generated summary files were uploaded centrally for phenotype 11 
quality approval of the generated phenotypes. GWAS were then run within each study 12 
and uploaded centrally. GWAS QC was performed using GWAtoolbox52 and custom 13 
scripts to assess ancestry-matching allele frequencies and fix variant positions. All 14 
studies had their own research protocols approved by the respective local ethics 15 
committees. All participants in all studies provided written informed consent.  16 
 17 
Phenotype definition 18 
Each study measured serum creatinine and blood urea nitrogen (BUN) as described in 19 
Supplementary Table 1. When measured with a Jaffé assay before 2009, serum 20 
creatinine values were calibrated by multiplying by 0.95.53 In studies of >18 year-old 21 
adults, eGFR was estimated with the Chronic Kidney Disease Epidemiology 22 
Collaboration (CKD-EPI) equation,54 using the R software package ‘nephro’.55 In studies 23 
of ≤18 year-old subjects, eGFR was estimated with the Schwartz formula56. eGFR 24 
values were winsorized at 15 and 200 ml/min/1.73 m2. CKD was defined as eGFR 25 
<60 ml/ min/1.73 m2. BUN was derived for studies that reported blood urea 26 
measurements by multiplication by 2.8, and units were aligned to mg/dl across cohorts. 27 
All steps occurred in the central phenotyping script. 28 
 29 
27 
Genotyping and genotype imputation 1 
Genotype imputation was conducted based on the Haplotype Reference Consortium 2 
(HRC) version 1.1 or the 1000 Genomes Project phase 3 version 5 (1000Gp3v5) ALL or 3 
phase 1 version 3 (1000Gp1v3) ALL panels. Imputed variants were coded as allelic 4 
dosages accompanied by the corresponding imputation quality (IQ) scores (ImputeV2 5 
info score, MACH/minimac RSQ, or as applicable), and annotated on the NCBI b37 6 
(hg19) reference build. Study-specific genotyping arrays as well as haplotype phasing 7 
and genotype imputation methods are described in Supplementary Table 2. 8 
 9 
Genome-wide association studies (GWAS) 10 
In each study, eGFR residuals were derived from sex- and age-adjusted linear 11 
regression models fitted to log(eGFR) and BUN using the centrally distributed script. In 12 
the subsequent GWAS, residuals were regressed on SNP dosage levels, assuming an 13 
additive genetic model. Study-specific features, such as study site, genetic principal 14 
components (PCs), or relatedness, were accounted for in the study-specific models as 15 
appropriate (Supplementary Table 2). Logistic regression models were fitted for CKD. 16 
 17 
Trans-ethnic GWAS meta-analysis  18 
For eGFR, 121 GWAS summary statistics files were contributed across studies. After 19 
QC, the total samples size was 765,348 (567,460 individuals of European ancestry 20 
[EA], 165,726 of East Asian ancestry, 13,842 African Americans, 13,359 of South Asian 21 
ancestry, and 4961 Hispanics; Supplementary Table 1). For CKD, 60 GWAS summary 22 
files were contributed, totaling a post-QC samples size of 625,219 (64,164 cases). For 23 
BUN, 65 GWAS summary files were contributed, totaling a post-QC samples size of 24 
416,178 (see Supplementary Table 1 for ancestry-specific details of CKD and BUN). 25 
Before meta-analysis, study-specific GWAS files were filtered to retain only 26 
variants with IQ score >0.6 and minor allele count (MAC) >10. Within study, we 27 
estimated the genomic control (GC) factor λGC and applied GC correction when λGC was 28 
>1. Fixed effects inverse-variance weighted meta-analysis was performed using 29 
28 
METAL,57 which was adapted to increase effects and standard errors precision (seven 1 
decimal places instead of four). 2 
After meta-analysis of 43,994,957 SNPs, we retained only variants that were 3 
present in ≥50% of the GWAS data files and had a total MAC of ≥400. Across 4 
ancestries, this yielded 8,221,591 variants for eGFR (8,834,748 in EA), 8,176,554 5 
variants for BUN (8,358,347 in EA), and 9,585,923 variants for CKD. Post-meta-6 
analysis GC correction was not applied because the LD Score regression intercept was 7 
close to 1 in all analyses of eGFR, BUN, and CKD.58 The genome-wide significance 8 
level was set at 5×10-8. Between-study heterogeneity was assessed using the I2 9 
statistic.59 For CKD, variants with an I2 ≥95% were removed to avoid exaggerated 10 
influence of single large studies. Variants were assigned to loci by selecting the SNP 11 
with the lowest p-value genome-wide as the index SNP, defining the corresponding 12 
locus as the 1 Mb-segment centered on the index SNP, and repeating the procedure 13 
until no further genome-wide significant SNPs remained. A locus was considered novel 14 
if it did not contain any variant identified by previous GWAS of eGFR. 15 
 16 
Meta-regression analysis of trans-ethnic GWAS 17 
For eGFR, we evaluated heterogeneity attributable to ancestry using quality-controlled 18 
study-specific GWAS files and the software Meta-Regression of Multi-Ethnic Genetic 19 
Association (MR-MEGA v0.1.2.26). Meta-regression models included three axes of 20 
genetic variation. GC correction was applied to the meta-regression results. For the 308 21 
genome-wide significant index SNPs from the trans-ethnic GWAS meta-analysis, we 22 
tested ancestry-related heterogeneity of allelic effects at a significance level of 0.05/308 23 
= 1.6×10-4 (indicating the corresponding p-value as p-anc-het). 24 
 25 
Proportion of phenotypic variance explained and genetic heritability analysis 26 
The proportion of phenotypic variance explained by the index SNPs was estimated as 27 
𝛽2 (
2𝑝(1−𝑝)
𝑣𝑎𝑟
), with β being the SNP effect, p the effect allele frequency, and var the 28 
variance of the sex- and age-adjusted log(eGFR) residuals (assumed as 0.016 based 29 
29 
on data from 11,827 EA participants of the population-based ARIC study).9 The 1 
proportion of variance explained by independent genome-wide significant index SNPs 2 
was estimated using the GCTA COJO Slct analysis (see fine-mapping section below). 3 
Genetic heritability of age- and sex-adjusted log(eGFR) was estimated using the 4 
R package ‘MCMCglmm’60 in the Cooperative Health Research In South Tyrol (CHRIS) 5 
study,61 a participating pedigree-based study of EA individuals (186 up-to-5 generation 6 
pedigrees, totaling 4373 subjects).62 We fitted two models, with and without the 7 
inclusion of the identified index variants (304/308 and 277/277 from the transethnic and 8 
EA analyses, respectively), running 1,000,000 MCMC iterations (burn in = 500,000) 9 
based on previously described settings.62  10 
30 
Comparison with and replication of results in the Million Veteran’s Program (MVP)  1 
To understand the robustness and generalizability of the eGFR-associated SNPs 2 
identified in the CKDGen Consortium, we interrogated the effect estimates of the 308 3 
trans-ethnic index SNPs in a GWAS from an independent, large, trans-ethnic study, the 4 
Million Veteran Program (MVP).27 Briefly, the MVP study participants were recruited 5 
across 63 U.S. Veteran’s Administration (VA) medical facilities. Written informed 6 
consent was obtained and all documents and protocols were approved by the VA 7 
Central Institutional Review Board. DNA was genotyped using a customized Affymetrix 8 
Axiom Biobank Array chip with additional content added to provide coverage of African 9 
and Hispanic haplotypes, as well as markers for common diseases in the VA 10 
population. After QC, genotype were pre-phased using EAGLE version 263 and imputed 11 
based on the 1000Gp3v5 reference panel using minimac3.64 Genotype PCs were 12 
estimated using FlashPCA.65 Serum creatinine was assessed up to one year prior to 13 
MVP enrollment using isotope dilution mass spectrometry. eGFR was estimated using 14 
the CKD-EPI equation54 after excluding subjects on dialysis, transplant patients, 15 
amputees, individuals on HIV medications, and those with creatinine values of <0.4 16 
mg/dl. Diabetes was defined as use of anti-diabetic medications or by assignment of an 17 
International Classification of Diseases 9 (ICD-9) code for diabetes during the baseline 18 
period. Hypertension was defined as having an ICD-9 code for hypertension, being on 19 
antihypertensive drug or having ≥2 measures of systolic or diastolic blood pressure 20 
>140 mmHg or >90 mmHg, respectively.  21 
GWAS of eGFR on SNP dosage levels were performed by fitting linear 22 
regression models adjusted for age at creatinine measurement, age2, sex, body mass 23 
index, and the first 10 genetic PCs, using SNPTEST version 2.5.4-beta.66 All GWAS 24 
were stratified by self-reported ethnicity (79.6% White non-Hispanic and 20.4% Black 25 
non-Hispanic), diabetes, and hypertension status. Results were combined across strata 26 
using fixed effects inverse-variance weighted meta-analysis in METAL.57 This analysis 27 
encompassed a total of 280,722 subjects across all strata, of whom 216,518 were non-28 
Hispanic Whites (EA). 29 
31 
Of the 308 trans-ethnic eGFR index variants, 305 variants or their good proxies 1 
were available for replication in the MVP GWAS (proxies had to have r2≥0.8 with the 2 
index SNP and were selected by maximum r2 followed by minimum distance in case of 3 
ties). Replication testing of the 256 EA-specific index SNPs was restricted to the MVP 4 
EA GWAS. CKDGen and MVP meta-analysis results were pooled via sample size 5 
weighted meta-analysis of z-scores using METAL.57 In both the trans-ethnic and EA-6 
specific analyses, replication was defined as a one-sided p-value <0.05 in the MVP and 7 
genome-wide significance of the CKDGen and MVP meta-analysis result. 8 
 9 
Classification of kidney function relevance of eGFR-associated loci based on BUN 10 
We used genetic associations with BUN to classify replicated index SNPs for eGFR with 11 
respect to their potential kidney function relevance into three tiers of evidence: tier 1 12 
(“strong support for kidney function relevance”) included all eGFR index SNPs with an 13 
inverse, significant (one-sided P<0.05) association with BUN for a given reference 14 
allele, tier 2 (“inconclusive evidence of kidney function relevance”) included all eGFR 15 
index SNPs whose effect on BUN was not significantly different from 0 (one-sided 16 
P>0.05); and tier 3 (“kidney function relevance is unlikely”) included all eGFR index 17 
SNPs with a concordant, significant (one-sided P<0.05) association with BUN for a 18 
given reference allele. 19 
 20 
Genetic risk score analysis in the UK Biobank dataset 21 
Genetic risk score (GRS) analyses were carried out based on summary statistics from 22 
452,264 participants of the UK Biobank. Genome-wide association results were 23 
obtained from GeneAtlas67 for the following ICD-10 codes: glomerular diseases (N00-24 
N08; number of cases: 2289); acute renal failure (N17; 4913); chronic renal failure (N18; 25 
4905); urolithiasis (N20-N23; 7053); hypertensive diseases (I10-I15; 84,910); and 26 
ischemic heart diseases (I20-I25; 33,387). Asthma (J45; 28,628) and schizophrenia 27 
(F20; 590) were included as negative controls. Of the 308 eGFR index SNPs from the 28 
trans-ethnic GWAS meta-analysis, 302 were available in the UK Biobank dataset. A 29 
32 
genetic risk score was estimated as the combined effect of alleles associated with lower 1 
eGFR levels at each of the 302 SNPs. The coefficient and standard error of the risk 2 
score is a weighted mean of the per-SNP regression coefficients (matched to the eGFR-3 
decreasing allele) and the combined squared standard errors, respectively, where each 4 
is weighted by the effect size of the respective allele from the eGFR CKDGen discovery 5 
meta-analysis.68 The same analysis was repeated restricted to 250 replicated SNPs 6 
with kidney function relevance of tier 1 or 2, of which 245 were present in the UK 7 
Biobank dataset and were used for GRS calculation (Supplementary Figure 5). 8 
 9 
Genome-wide genetic correlations with other complex traits and diseases  10 
Genome-wide genetic correlation analysis was carried out to investigate evidence of co-11 
regulation or shared genetic bases between eGFR and BUN and other complex traits 12 
and diseases, both known and not known to correlate with eGFR and BUN. We 13 
estimated pairwise genetic correlation coefficients (rg) between the results of our trans-14 
ethnic meta-analyses of eGFR and BUN and each of 749 pre-computed and publicly 15 
available GWAS summary statistics of complex traits and diseases available through LD 16 
Hub version 1.9.0 using LD Score regression.28 An overview of the sources of these 17 
summary statistics and their corresponding sample sizes is available at 18 
http://ldsc.broadinstitute.org. Statistical significance was assessed at the Bonferroni 19 
corrected level of 6.7×10-5 (=0.05/749). 20 
 21 
Functional enrichment: pathway and tissue enrichment analysis 22 
We used DEPICT version 1 release 194 to perform Data-Driven Expression 23 
Prioritized Integration for Complex Traits analysis,29 including pathway/gene-set 24 
enrichment and tissue/cell type analyses as described previously.9,10 All 14,461 gene 25 
sets were reconstituted by identifying genes that were transcriptionally co-regulated with 26 
other genes in a panel of 77,840 gene expression microarrays,69 from mouse knock-out 27 
studies, and molecular pathways from protein-protein interaction screening. In the 28 
tissues and cell type enrichment analysis, we tested whether genes in associated 29 
33 
regions were highly expressed in 209 MeSH annotation categories for 37,427 1 
microarrays on the Affymetrix U133 Plus 2.0 Array platform. For both eGFR and BUN, 2 
we included all variants associated with the trait at a p-value of <5×10-8 in the trans-3 
ethnic meta-analysis. Independent variant clumping was performed using Plink 1.970 4 
with 500 kb flanking regions and r²>0.01 in the 1000Gp1v3 dataset. After excluding the 5 
MHC region, DEPICT was run with 500 repetitions to estimate the FDR and 5000 6 
permutations to compute p-values adjusted for gene length by using 500 null GWAS. All 7 
significant gene sets were merged into meta gene sets by running an affinity 8 
propagation algorithm71 implemented in the Python ‘scikit-learn’ package (http://scikit-9 
learn.org/). The resulting network was visualized using Cytoscape 10 
(http://cytoscape.org/). 11 
 12 
Enrichment of heritability by cell type group  13 
We used stratified LD Score regression as a complementary method to investigate 14 
important tissues and cell types based on the trans-ethnic eGFR and BUN meta-15 
analysis results. Heritability enrichment in 10 cell type groups was assessed using the 16 
default options of stratified LD Score regression described previously.30 The 10 cell type 17 
groups were collapsed from 220 cell-type specific regulatory annotations for the four 18 
histone marks H3K4me1, H3K4me3, H3K9ac, and H3K27ac. The enrichment of a cell 19 
type category was defined as the proportion of SNP heritability in that group divided by 20 
the proportion of SNPs in the same cell type group. 21 
 22 
Identification of variants in genes causing kidney phenotypes in mice  23 
A nested candidate gene analysis was performed using GenToS72 to identify additional 24 
genetic associations that were missing conventional genome-wide statistical 25 
significance. Candidate genes causing kidney phenotypes in mice upon manipulation 26 
were selected using the comprehensive Mouse Genome Informatics (MGI) phenotype 27 
ontology in September 2017 (abnormal renal glomerular filtration rate [MP:0002847]; 28 
abnormal kidney morphology [MP:0002135]; abnormal kidney physiology 29 
34 
[MP:0002136]). The human orthologs of these genes were obtained using the Human-1 
Mouse: Disease Connection webtool 2 
(http://www.informatics.jax.org/humanDisease.html). Genes with no human orthologs 3 
were removed. Statistical significance was defined as a Bonferroni correction of a type I 4 
error level of 0.05 for the number of independent common SNPs across all genes in 5 
each of the three candidate gene lists plus their flanking regions, based on an ancestry-6 
matched reference population. In a next step, the GWAS meta-analysis summary 7 
statistics for eGFR were queried for significantly associated SNPs mapping into the 8 
selected candidate genes. Enrichment of significant genetic associations in genes within 9 
each candidate list was computed from the complementary cumulative binomial 10 
distribution.72 GenToS was used with default parameters on each of the three candidate 11 
gene lists, using the 1000 Genomes phase 3 release 2 ALL dataset as reference.  12 
 13 
Identification of independent variants in the EA meta-analysis 14 
To identify additional, independent eGFR-associated variants within the identified loci, 15 
approximate conditional analyses were carried out that incorporated LD information 16 
from an ancestry-matched reference population. We used the genome-wide eGFR 17 
summary statistics from the EA meta-analysis as input, because an LD reference 18 
sample scaled to the size of our meta-analysis was only available for EA individuals.32 19 
We randomly selected 15,000 participants from the UK Biobank dataset (UKBB; dataset 20 
ID 8974). Individuals who withdrew consent and those not meeting data cleaning 21 
requirements were excluded, keeping only those who passed sex-consistency check, 22 
had ≥95% call rate, and did not represent outliers with respect to SNP heterozygosity. 23 
For each pair of individuals, the proportion of variants shared identical-by-descent (IBD) 24 
was computed using PLINK.73 From pairs with IBD coefficient ≥0.1875 we retained only 25 
one member. Individuals were restricted to those of EA by excluding outliers along the 26 
first two PCs from a principal component analysis seeded with the HapMap phase 3 27 
release 2 populations as reference. The final dataset to estimate LD included 13,558 EA 28 
individuals and 16,969,363 SNPs.  29 
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The basis for statistical fine-mapping were the 256 1-Mb genome-wide significant 1 
loci identified in the EA meta-analysis, clipping at chromosome borders. Overlapping 2 
loci as well as pairs of loci whose respective index SNPs were correlated (r² >0.1 in the 3 
UKBB LD dataset described above) were merged. A single SNP was chosen to 4 
represent the MHC region, resulting in a final list of 212 regions prior to fine-mapping. 5 
Within each region, the GCTA COJO Slct algorithm74 was used to identify independent 6 
variants employing a step-wise forward selection approach. We used the default 7 
collinearity cut-off of 0.9 (sensitivity analyses showing no major influence of alternative 8 
cutoff values; data not shown). We deemed an additional SNP as independently 9 
genome-wide significant if the SNPs’ p-value conditional on all previously identified 10 
SNPs in the same region was <5×10-8.  11 
 12 
Statistical fine-mapping and credible set generation in the EA meta-analysis 13 
Statistical fine-mapping was carried out for each of the 212 regions. For each region 14 
containing multiple independent SNPs and for each independent SNP in such regions, 15 
approximate conditional analyses were carried out using the GCTA COJO-Cond 16 
algorithm to generate approximate conditional association statistics conditioned on the 17 
other independent SNPs in the region. Using the Wakefield’s formula implemented in 18 
the R package ’gtx’,75 we derived approximate Bayes factors (ABF) from conditional 19 
estimates in regions with multiple independent SNPs and from the original estimates for 20 
regions with a single independent SNP. Given that 95% of the SNP effects on 21 
log(eGFR) fell within the -0.01 to 0.01 interval, the standard deviation prior was chosen 22 
as 0.0051 based on formula no. 8 in the original publication.33 Sensitivity analyses 23 
showed that results were robust when higher values were used for the standard 24 
deviation prior (data not shown). For each variant within an evaluated region, the ABF 25 
obtained from the association betas and their standard errors of the marginal (single 26 
signal region) or conditional estimates (multi-signal regions) was used to calculate the 27 
posterior probability (PP) for the variant driving the association signal (“causal variant”). 28 
Ninety-nine percent credible sets, representing the set of SNPs that contain the causal 29 
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variant(s) with 99% probability, were computed by ranking variants by their PP and 1 
adding them to the set until the cumulative PP was >99% in each region.  2 
 3 
Variant annotation 4 
Functional annotation of variants mapping into credible sets was performed by querying 5 
the SNiPA database version 3.2 (March 2017),76 based on the 1000Gp3v5 and 6 
Ensembl version 87 datasets. SNiPA was also used to derive the Combined Annotation 7 
Dependent Depletion (CADD) PHRED-like score,77 based on CADD version 1.3. The 8 
Ensembl VEP tool78 was used for SNP’s primary effect prediction. 9 
 10 
Co-localization analysis of associations with eGFR and gene expression (cis-eQTLs) 11 
As the great majority of gene expression datasets is generated based on EA ancestry 12 
samples, co-localization analysis was based on the genetic associations with eGFR in 13 
the EA sample and with gene expression quantified from micro-dissected human 14 
glomerular and tubulo-interstitial kidney portions from 187 individuals participating in the 15 
NEPTUNE study,47 as well as from the 44 tissues included in the GTEx Project version 16 
6p release.41 The eQTL and GWAS effect alleles were harmonized. For each locus, we 17 
identified tissue gene pairs with reported eQTL data within ±100 kb of each GWAS 18 
index variant. The region for each co-localization test was defined as the eQTL cis 19 
window defined in the underlying GTEx and NephQTL studies. We used the default 20 
parameters and prior definitions set in the ‘coloc.fast’ function from the R package ‘gtx’ 21 
(https://github.com/tobyjohnson/gtx), which is an adaption of Giambartolomei’s 22 
colocalization method.79 The package was also used to estimate the direction of effect 23 
over the credible sets as the ratio of the average PP weighted GWAS effects over the 24 
PP weighted eQTL effects.  25 
 26 
Trans-eQTL analysis 27 
We performed trans-eQTL annotation through LD mapping based on the 1000Gp3v5 28 
European reference panel with an r2 cut-off of >0.8. We limited annotation to index 29 
37 
SNPs with a fine-mapping posterior probability ≥1% in at least one fine-mapping-region. 1 
Due to expected small effect sizes, only genome-wide trans-eQTL studies of either 2 
peripheral blood mononuclear cells or whole blood with a sample size of ≥1000 3 
individuals were considered, resulting in five non-overlapping studies80-84 4 
(Supplementary Table 15). For the study by Kirsten et al,84 we had access to an 5 
update with larger sample size combining two non-overlapping studies (LIFE-Heart85 6 
and LIFE-Adult86) resulting in a total sample size of 6645. To improve stringency of 7 
results, we focused the analysis on inter-chromosomal trans-eQTLs with P<5×10-8 8 
reported by ≥2 studies.  9 
 10 
Co-localization analyses with urinary uromodulin concentrations 11 
Association between concentrations of the urinary uromodulin-to-creatinine ratio with 12 
genetic variants at the UMOD-PDILT locus were evaluated in the German Chronic 13 
Kidney Disease (GCKD) study.87 Uromodulin concentrations were measured from 14 
frozen stored urine using an established ELISA assay with excellent performance as 15 
described previously.37 Concentrations were indexed to creatinine to account for urine 16 
dilution. Genetic associations were computed using the same software and settings as 17 
for the association with eGFR (Supplementary Table 2). Co-localization analyses were 18 
carried out using identical software and settings as described above for the association 19 
with gene expression. 20 
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Figure Legends 1 
 2 
Figure 1 – Trans-ethnic GWAS meta-analysis identifies 308 loci associated with 3 
eGFR  4 
Circos plot: Red band: –log10(P) for association with eGFR, by chromosomal position. 5 
Blue line indicates genome-wide significance (P=5×10-8). Black gene labels indicate 6 
novel loci, blue labels known loci. Non-replicating loci are colored in gray (novel) or light 7 
blue (known). Green band: Measures of heterogeneity related to the index SNPs 8 
associated with eGFR. Dot sizes are proportional to I² or ancestry-related heterogeneity 9 
(p-anc-het). Blue band: –log10(P) for association with CKD, by chromosomal position. 10 
Red line indicates genome-wide significance (P=5×10-8). Radial lines mark regions with 11 
p-anc-het <1.6×10-4 = 0.05/308 or I² >25%. Inset: Effects of all 308 index SNPs on 12 
log(eGFR) by their minor allele frequency, color-coded by the associated odds ratio 13 
(OR) of CKD (red scale for OR≤1, blue scale for OR>1). Triangles highlight SNPs that 14 
were significantly (P<1.6×10-4 =0.05/308) associated with CKD. 15 
 16 
Figure 2 – Generalizability with respect to other populations and other kidney 17 
function markers 18 
Panel A: Measures of heterogeneity for 308 eGFR-associated index SNPs. 19 
Comparison of each variant’s heterogeneity quantified as I² from the trans-ethnic meta-20 
analysis (Y-axis) vs. ancestry-related heterogeneity from meta-regression (-log10(p-anc-21 
het), X-axis). Histograms summarize the distribution of the heterogeneity measures on 22 
both axes. SNPs with ancestry-related heterogeneity (p-anc-het<1.6×10-4 = 0.05/308) 23 
are marked in blue and labeled; SNPs with I²>50% are labeled. Panel B: Comparison 24 
of genetic effect sizes between CKDGen Consortium data (X-axis) and MVP data 25 
(Y-axis). Blue font indicates P<1.6×10-4 (0.05/308) in the MVP. Error bars indicate 95% 26 
CIs. Dashed line: line of best fit. Panel C: Comparison of the magnitude of the 27 
effects on eGFR (X-axis) vs. BUN (Y-axis) for the 308 eGFR-associated index 28 
SNPs. SNPs are marked in blue when P<1.6×10-4 (0.05/308) in the BUN analysis. Error 29 
45 
bars indicate 95% CIs. Dashed line: line of best fit. Panel D: Association between a 1 
genetic risk score (GRS) for low eGFR and clinical phenotypes abstracted from 2 
ICD-10 codes independent individuals from the UK Biobank. Asthma was included 3 
as a negative control. Displayed are odds ratios and their 95% CIs per standard 4 
deviation increase in GRS (Methods).  5 
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Figure 3 – Human orthologs of genes with renal phenotypes in genetically 1 
manipulated mice are enriched for association signals with eGFR 2 
Signals in candidate genes identified based on the murine phenotypes abnormal GFR 3 
(Panel A), abnormal kidney physiology (Panel B), and abnormal kidney morphology 4 
(Panel C). Y-axis: –log10(P) for association with eGFR in the trans-ethnic meta-analysis 5 
for the variant with the lowest p-value in each candidate gene. Dashed line indicates 6 
genome-wide significance (P=5×10-8), solid gray line indicates the experiment-wide 7 
significance threshold for each nested candidate gene analysis (included in lower right 8 
corner in each panel). Orange color indicates genome-wide significance, red color 9 
experiment-wide but not genome-wide significance, and blue color indicates genes with 10 
no significantly associated SNPs. Genes are labeled when reaching experiment- but not 11 
genome-wide significance; black font for genes not mapping into loci reported in the 12 
main analysis, gray font otherwise. Enrichment p-value reported for observed number of 13 
genes with association signals below the experiment-wide threshold against the 14 
expected number based on the complementary cumulative binomial distribution 15 
(Methods). 16 
 17 
Figure 4 – Credible set size (X-axis) against variant posterior probability (Y-axis) 18 
of 3655 variants in 252 99% credible sets by annotation 19 
Panel A: Exonic variants. Variants are marked by triangles, with size proportional to 20 
their CADD score. Red triangles and variant labeling indicate missense variants 21 
mapping into small (≤5 SNPs) credible sets or with high individual posterior probability 22 
of driving the association signal (>0.5). Panel B: Regulatory potential. Symbol colors 23 
identify variants with regulatory potential as derived from DNAse hypersensitivity 24 
analysis in target tissues (Methods). Variant annotation was restricted to variants with 25 
variant posterior probability >1%; SNPs with posterior probability ≥90% contained in 26 
credible sets with ≤10 variants were labeled. 27 
 28 
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Figure 5 – Co-localization of eGFR-association signals with gene expression in 1 
kidney tissues 2 
All eGFR loci were tested for co-localization with all eQTLs where the eQTL cis-window 3 
overlapped (±100 kb) the sentinel genetic variants. Genes with ≥1 positive co-4 
localization (posterior probability of one common causal variant, H4, ≥0.80) in a kidney 5 
tissue are illustrated with the respective sentinel variants (Y-axis). Co-localizations 6 
across all tissues (X-axis) are illustrated as dots, where the size of the dots indicates the 7 
posterior probability of the co-localization. Negative co-localizations (posterior 8 
probability of H4 <0.80) are marked in grey, while the positive co-localizations are color-9 
coded based on the predicted change in expression relative to the allele associated with 10 
lower eGFR. 11 
 12 
Figure 6 – Co-localization of independent eGFR-association signals at the UMOD-13 
PDILT locus with urinary uromodulin concentrations supports UMOD as the 14 
effector gene. 15 
Association plots: association –log10(p-value) (Y axis) vs. chromosomal position (X 16 
axis). Approximate conditional analyses among EA individuals support the presence of 17 
two independent eGFR-associated signals (Panel A). The association signal with 18 
urinary uromodulin/creatinine levels looks similar (Panel B). Co-localization of 19 
association with eGFR (upper sub-panel) and urinary uromodulin/creatinine levels 20 
(lower sub-panel) for the independent regions centered on UMOD (Panel C) and PDILT 21 
(Panel D) support a shared underlying variant in both regions with high posterior 22 
probability.  23 
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Table 1 – Genes implicated as causal via identification of missense variants with high probability of driving the 
eGFR association signal. Genes are included if they contain a missense variant with posterior probability of association 
of >50% or mapping into a small credible set (≤5 variants). 
Gene SNP Credible 
set size 
SNP 
PP
1
 
functional 
consequence 
CADD 
score
2
 
DHS
3
, 
tissue 
Brief summary of the gene’s function and relevant literature (OMIM entries are indicated as #number) 
CACNA1S rs3850625 1 1.00 p.Arg1539Cys 
(NP_000060.2) 
34.0 - Encodes a subunit of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle. Reports of altered 
expression in kidney cancer (PMID 28781648) and after indoxyl sulfate treatment (PMID: 27550174). Rare variants can cause 
autosomal dominant hypokalemic periodic paralysis, type 1 (#170400) or malignant hyperthermia susceptibility (#601887). 
Common variation at this locus has been reported as associated with eGFR in previous GWAS (PMID: 24029420, PMID: 26831199). 
EDEM3 rs78444298 1 1.00 p.Pro746Ser 
(NP_079467.3) 
24.6 - The gene product accelerates the glycoprotein ER-associated degradation by proteasomes by catalyzing mannose trimming from 
Man8GlcNAc2 to Man7GlcNAc2 in the N-glycans. This variant has been identified by a previous exome chip association study with 
eGFR (PMID: 27920155). 
KLHDC7A rs11261022 7 0.71 p.Arg160Ser 
(NP_689588.2) 
1.1 Roadmap, 
ENCODE 
kidney 
Kelch Domain Containing 7A is a protein coding gene and a paralog of KBTBD11. No specific entry in relation to kidney disease in 
PubMed.  
RPL3L rs113956264 1 1.00 p.Val262Met 
(NP_005052.1) 
27.2 - The gene product shares sequence similarity with ribosomal protein L3. It has a tissue-specific expression pattern, with highest 
levels in skeletal muscle and heart. 
SLC25A45 rs34400381 1 1.00 p.Arg285Cys 
(NP_00107070
9.2) 
26.0 ENCODE 
kidney 
Belongs to the SLC25 family of mitochondrial carrier proteins and is an orphan transporter. This variant has already been identified 
in a GWAS of symmetric dimethylarginine levels (PMID: 24159190) and in a whole-genome sequence (WGS) analysis of serum 
creatinine (PMID: 25082825). SLC25A45 may play a role in biosynthesis of arginine, which is involved in the synthesis of creatine.  
SLC47A1 rs111653425 1 1.00 p.Ala465Val 
(NP_060712.2) 
24.6 - Encodes the multidrug and toxin extrusion protein (MATE1), a transport protein responsible for the secretion of cationic drugs and 
creatinine across brush border membranes. This variant has already been identified in a WGS analysis of serum creatinine from 
Iceland (PMID: 25082825). Rare and common variants in the locus have been identified in exome chip (PMID: 27920155) and in 
GWAS (PMID: 20383146) studies of eGFR, respectively. MATE1 knockout (KO) mice show higher levels of serum creatinine and BUN 
(PMID: 19332510), arguing against a sole effect on creatinine transport and supporting an effect on kidney function.  
PPM1J rs34611728 5 0.02 p.Leu213Phe 
(NP_005158.5) 
13.1 ENCODE 
kidney 
This gene encodes the serine/threonine protein phosphatase. The variant has been reported in association with eGFR in an exome 
chip association study (PMID: 27920155). 
CERS2 rs267738 5 0.46 p.Glu115Ala 
(NP_071358.1) 
32.0/ 
28.2 
- Encodes Ceramide Synthase 2, which may be involved in sphingolipid synthesis. Changes in ceramides were reported as essential in 
renal Madin-Darby Canine Kidney (MDCK) cell differentiation (PMID: 28515139). CERS2 KO mice show strongly reduced ceramide 
levels in the kidney and develop renal parenchyma abnormalities (PMID: 19801672). This variant has been reported as associated 
with the rate of albuminuria increase in patients with diabetes (PMID: 25238615). 
C9 rs700233 5 0.32 p.Arg5Trp 
(NP_001728.1) 
6.6 - Encodes a constituent of the membrane attack complex that plays a key role in the innate and adaptive immune response. Rare 
mutations can cause C9 deficiency (#613825). C9 is mentioned in several kidney disease case reports, including patients with 
congenital factor 9 deficiency showing IgA nephropathy (PMID: 1453611).  
SLC22A2 rs316019 4 0.04 p.Ser270Ala 
(NP_003049.2) 
12.7 - Encodes the polyspecific organic cation transporter (OCT2) that is primarily expressed in the kidney, where it mediates tubular uptake 
of organic compounds including creatinine from the circulation. Many publications relate SLC22A2 to kidney function. rs316019 is a 
known pharmacogenomics variant associated with response to metformin and other drugs such as cisplatin. Carriers of the risk allele 
have a higher risk of cisplatin-induced nephrotoxicity (PMID: 19625999), indicating that this transporter is essential in excreting 
toxins. The locus has been reported in previous GWAS of eGFR (PMID: 20383146). 
 
1
PP: posterior probability. 
2
CADD score: Combined Annotation Dependent Depletion (CADD) PHRED-like score (Methods); 
3
DHS: DNAse Hypersensitivity Site 
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